1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents

PCT No. PCT/US96/09498 Sec. 371 Date Feb. 11, 1998 Sec. 102(e) Date Feb. 11, 1998 PCT Filed Jun. 6, 1996 PCT Pub. No. WO96/40126 PCT Pub. Date Dec. 19, 1996The present invention is directed to 1H-4(5)-substituted imidazole derivates of formula (I), wherein A is (a); (b); or (c) wherein R1 is lower a...

Full description

Saved in:
Bibliographic Details
Main Authors TEDFORD; CLARK E, PHILLIPS; JAMES G, KHAN; AMIN MOHAMMED
Format Patent
LanguageEnglish
Published 06.06.2000
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:PCT No. PCT/US96/09498 Sec. 371 Date Feb. 11, 1998 Sec. 102(e) Date Feb. 11, 1998 PCT Filed Jun. 6, 1996 PCT Pub. No. WO96/40126 PCT Pub. Date Dec. 19, 1996The present invention is directed to 1H-4(5)-substituted imidazole derivates of formula (I), wherein A is (a); (b); or (c) wherein R1 is lower alkyl or lower alkoxy; R2, R3, R4, R5, R7 and R8 are each independently hydrogen or lower alkyl; R6 is hydrogen, lower alkyl or lower alkoxy and R5 and R6 can be joined to form a 4, 5 or 6 membered ring. The compounds of formula (I) have H3 histamine receptor agonist activity. The pharmaceutically acceptable salts, and individual stereoisomers of compounds of formula (I) above, as well as mixtures thereof, are also contemplated as falling within the scope of the present invention. The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of formula (1). The present invention also provides a method of treating conditions in which activation of histamine H3 receptors may be of therapeutic importance such as allergy, inflammation, cardio or cerebrovascular disease, gastrointestinal disorders and CNS disorders involving psychiatric disorders.
Bibliography:Application Number: US19980973121